Krystal Biotech (FRA:4KB) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €303.60
GF Value €263.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Krystal Biotech's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:4KB vs NUVL, PRAX, TECH: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Krystal Biotech's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Margin of Safety % (DCF FCF Based) falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€303.60
Price
€263.13
GF Value